Clinical Study on the Efficacy of Theravex Oral and Theravex Tissue Care Plus in Periodontal Surgery Modified Free Gingival Graft for RT1-RT2 Gingival Recession: A Randomized Clinical Trial

What this Trial Is About

Researchers are evaluating two new bioactive solutions, Theravex Oral and Theravex Tissue Care Plus, to improve soft tissue healing after periodontal surgery. The study focuses on patients with gingival recession around mandibular incisors undergoing a Modified Free Gingival Graft (M-FGG) technique. This randomized, double-blind trial aims to measure the impact of these solutions on root coverage, tissue gain, color integration, and postoperative pain over a one-year period. Participants are randomly assigned to either the test group receiving the M-FGG surgery combined with Theravex Tissue Care Plus applied to the graft and recipient site, followed by twice-daily rinsing with Theravex Oral for 14 days, or the control group receiving the same surgery with a saline placebo solution and rinsing with a blinded cetylpyridinium chloride solution. The solutions are applied immediately after graft harvesting and prior to graft placement. During the study, participants are followed at 1, 3, 6, and 12 months post-surgery for clinical exams and professional hygiene. Researchers assess outcomes including recession depth reduction, keratinized tissue width, soft tissue thickness, tissue color integration, microvascular perfusion, and soft tissue volume changes using digital 3D scanning, spectrophotometry, ultrasonography, and laser imaging. Patient-reported pain and aesthetic perceptions are also recorded.

Theravex Oral and Theravex Tissue Care Plus in the Healing Process of Mucogingival Surgery